» Articles » PMID: 27466189

HDAC4: a Key Factor Underlying Brain Developmental Alterations in CDKL5 Disorder

Overview
Journal Hum Mol Genet
Date 2016 Jul 29
PMID 27466189
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclin-dependent kinase-like 5 (CDKL5) is a Ser/Thr protein kinase predominantly expressed in the brain. Mutations of the CDKL5 gene lead to CDKL5 disorder, a neurodevelopmental pathology that shares several features with Rett Syndrome and is characterized by severe intellectual disability. The phosphorylation targets of CDKL5 are largely unknown, which hampers the discovery of therapeutic strategies for improving the neurological phenotype due to CDKL5 mutations. Here, we show that the histone deacetylase 4 (HDAC4) is a direct phosphorylation target of CDKL5 and that CDKL5-dependent phosphorylation promotes HDAC4 cytoplasmic retention. Nuclear HDAC4 binds to chromatin as well as to MEF2A transcription factor, leading to histone deacetylation and altered neuronal gene expression. By using a Cdkl5 knockout (Cdkl5 -/Y) mouse model, we found that hypophosphorylated HDAC4 translocates to the nucleus of neural precursor cells, thereby reducing histone 3 acetylation. This effect was reverted by re-expression of CDKL5 or by inhibition of HDAC4 activity through the HDAC4 inhibitor LMK235. In Cdkl5 -/Y mice treated with LMK235, defective survival and maturation of neuronal precursor cells and hippocampus-dependent memory were fully normalized. These results demonstrate a critical role of HDAC4 in the neurodevelopmental alterations due to CDKL5 mutations and suggest the possibility of HDAC4-targeted pharmacological interventions.

Citing Articles

Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy.

Cao D, Zhou X, Guo Q, Xiang M, Bao M, He B Biomark Res. 2024; 12(1):142.

PMID: 39563472 PMC: 11575089. DOI: 10.1186/s40364-024-00687-6.


LMK235 ameliorates inflammation and fibrosis after myocardial infarction by inhibiting LSD1-related pathway.

Lv F, Xie L, Li L, Lin J Sci Rep. 2024; 14(1):23450.

PMID: 39379699 PMC: 11461967. DOI: 10.1038/s41598-024-74887-3.


Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia.

Verbeek T, Vrenken K, Arentsen-Peters S, Castro P, van de Ven M, van Tellingen O Commun Biol. 2024; 7(1):1257.

PMID: 39362994 PMC: 11450098. DOI: 10.1038/s42003-024-06916-w.


LMK-235 suppresses osteoclastogenesis and promotes osteoblastogenesis by inhibiting HDAC4.

Chen C, Li Y, Feng T, Chen X, Li C, Li L Sci Rep. 2024; 14(1):19973.

PMID: 39198677 PMC: 11358535. DOI: 10.1038/s41598-024-70814-8.


Novel CDKL5 targets identified in human iPSC-derived neurons.

Massey S, Ang C, Davidson N, Quigley A, Rollo B, Harris A Cell Mol Life Sci. 2024; 81(1):347.

PMID: 39136782 PMC: 11335273. DOI: 10.1007/s00018-024-05389-8.